eli lilly glp-1 receptor agonist products launches pill, kicking off showdown with Novo Nordisk Orforglipron: The First Approved Oral

The study identified significant reductions in medical claims, including: Digestive and GI cost reduction: - $9,240+ per member per year Obesity-related medical cost reduction: - $4,884+ per member per year Anxiety-related medical cost reduction : - $1,356+ per member per year Overall medical spend Reduction: -$3,012 per member per year Precision Biology as the New Standard of Care While most high-cost claimants are polychronic, traditional digital care programs treat these conditions in silos, resulting in fragmented care, poor engagement, overlapping medications, and escalating costs

Their ability to simultaneously address metabolic risk factors, inflammation, and cellular proliferation positions them as one of the most promising drug classes for interrupting SLD progression (Figure 2)

Some individuals may not feel any immediate difference, while others notice a gradual decrease in appetite or an earlier feeling of fullness during meals

Patients should not inject research-use or online products marketed as retatrutide

Clinical trials have demonstrated its efficacy, with participants achieving substantial weight loss compared to placebo

Behavioural interventions including cognitive behavioural therapy (CBT), mindful eating approaches, and structured weight management programmes can address psychological aspects of eating and support sustainable lifestyle changes